Hansa Medical to Host Conference Call to Provide Year-End Report 2018 Business Update
Lund, Sweden, January 31, 2019 – Hansa Medical AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa Medical” or the “Company”), under name change to Hansa Biopharma AB, a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that Hansa Medical will publish the 2018 Year-End Report on 8 February 2010, at 08:00AM CET, and that all interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s CEO and President, Søren Tulstrup, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference, please use the dial in details shown below:
SE: +46 856642705
UK: +44 3333009261
US: +1 6467224957
A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: https://financialhearings.com/event/11683
The information was submitted for publication, through the agency of the contact person set out below at 08:15am CET on January 31, 2019.
For further information, please contact:
Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477
E-mail: emanuel.bjorne@hansamedical.com
Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60
U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media)
+1 212 600 1902
About Hansa Medical
Hansa Medical (NASDAQ Stockholm:HNSA) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.
Tags: